Momordica charantia l. — diabetes-related bioactivities, quality control, and safety considerations

HIGHLIGHTS

  • who: Momordica charantia L.- and colleagues from the Department of Pharmaceutical Biology, Institute of Pharmacy, Kiel University, Kiel, Germany have published the article: Momordica charantia L. u2014 Diabetes-Related Bioactivities, Quality Control, and Safety Considerations, in the Journal: (JOURNAL) of 17/05/2022
  • how: All of the isolates were tested for their inhibition of u03b1-glucosidase however with no effect compared to acarbose.
  • future: Future studies should apply formulations (preferably made of extracts) with a defined amount of daily intake.

SUMMARY

    This shortcoming and the high bias associated with . . .

     

    Logo ScioWire Beta black

    If you want to have access to all the content you need to log in!

    Thanks :)

    If you don't have an account, you can create one here.

     

Scroll to Top

Add A Knowledge Base Question !

+ = Verify Human or Spambot ?